Mahajna, M.; Abu Fanne, R.; Berkovitch, M.; Tannous, E.; Vinker, S.; Green, I.; Matok, I.
Effect of CYP2C19 Pharmacogenetic Testing on Predicting Citalopram and Escitalopram Tolerability and Efficacy: A Retrospective, Longitudinal Cohort Study. Biomedicines 2023, 11, 3245.
https://doi.org/10.3390/biomedicines11123245
AMA Style
Mahajna M, Abu Fanne R, Berkovitch M, Tannous E, Vinker S, Green I, Matok I.
Effect of CYP2C19 Pharmacogenetic Testing on Predicting Citalopram and Escitalopram Tolerability and Efficacy: A Retrospective, Longitudinal Cohort Study. Biomedicines. 2023; 11(12):3245.
https://doi.org/10.3390/biomedicines11123245
Chicago/Turabian Style
Mahajna, Mahmood, Rami Abu Fanne, Matitiahu Berkovitch, Elias Tannous, Shlomo Vinker, Ilan Green, and Ilan Matok.
2023. "Effect of CYP2C19 Pharmacogenetic Testing on Predicting Citalopram and Escitalopram Tolerability and Efficacy: A Retrospective, Longitudinal Cohort Study" Biomedicines 11, no. 12: 3245.
https://doi.org/10.3390/biomedicines11123245
APA Style
Mahajna, M., Abu Fanne, R., Berkovitch, M., Tannous, E., Vinker, S., Green, I., & Matok, I.
(2023). Effect of CYP2C19 Pharmacogenetic Testing on Predicting Citalopram and Escitalopram Tolerability and Efficacy: A Retrospective, Longitudinal Cohort Study. Biomedicines, 11(12), 3245.
https://doi.org/10.3390/biomedicines11123245